Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339259 | 1.00 | CHRM3 (0.33) | CHRM3SIGMAR1CHRM4TNKSTNKS2 | |
| SCHEMBL339260 | 1.00 | CHRM3 (0.33) | CHRM3SIGMAR1CHRM4TNKSTNKS2 | |
| SCHEMBL1911445 | 0.80 | P2RX7 (0.38) | TNKSTNKS2PARP2ALDH1A1LMNA | |
| SCHEMBL338848 | 0.80 | P2RX7 (0.38) | TNKSTNKS2PARP2ALDH1A1LMNA | |
| SCHEMBL1912414 | 0.80 | P2RX7 (0.38) | TNKSTNKS2PARP2ALDH1A1LMNA | |
| SCHEMBL338577 | 0.79 | GSK3B (0.39) | CHRM3ALDH1A1DPP4 | |
| SCHEMBL338950 | 0.75 | ALDH1A1 (0.40) | ALDH1A1LMNAHTTCNR1DPP4 | |
| SCHEMBL340212 | 0.73 | DPP4 (0.39) | TNKSTNKS2PARP2ALDH1A1DPP4 | |
| SCHEMBL339777 | 0.73 | EPHX2 (0.38) | DPP4 | |
| SCHEMBL339881 | 0.72 | GSK3B (0.36) | CHRM3CNR1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | CHRM3 1268/4885SIGMAR1 270/4885CHRM4 1557/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | CHRM3 1268/4885SIGMAR1 270/4885CHRM4 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.